Literature DB >> 29474094

Natural History of Chronic Obstructive Pulmonary Disease Exacerbations in a General Practice-based Population with Chronic Obstructive Pulmonary Disease.

Kieran J Rothnie1,2, Hana Müllerová3, Liam Smeeth2, Jennifer K Quint1,2.   

Abstract

RATIONALE: Acute exacerbations of chronic obstructive pulmonary disease (AECOPDs) are important adverse events in the natural history of chronic obstructive pulmonary disease (COPD).
OBJECTIVES: To investigate the natural history of AECOPDs over 10 years of follow-up.
METHODS: We identified 99,574 patients with COPD from January 1, 2004, to March 31, 2015, from the UK Clinical Practice Research Datalink. We defined moderate AECOPDs as those managed outside hospital and severe as those requiring hospitalization. During the baseline period (first year of follow-up), patients were grouped according to the number and severity of AECOPDs and then followed for a maximum of 10 years (mean, 4.9 yr). We investigated the effect of baseline AECOPD number and severity on risk of further events and death.
MEASUREMENTS AND MAIN RESULTS: Around one-quarter of the patients with COPD did not exacerbate during follow-up. Compared with no AECOPDs in the baseline period, AECOPD number predicted the future long-term rate of AECOPDs in a graduated fashion, ranging from hazard ratio (HR) of 1.71 (1.66-1.77) for one event to HR of 3.41 (3.27-3.56) for five or more events. Two or more moderate AECOPDs were also associated with an increased risk of death in a graduated fashion, ranging from HR of 1.10 (1.03-1.18) for two moderate AECOPDs to HR of 1.57 (1.45-1.70) for five or more moderate AECOPDs, compared with those with no AECOPDs at baseline. Severe AECOPDs were associated with an even higher risk of death (HR, 1.79; 1.65-1.94).
CONCLUSIONS: A large proportion of patients with COPD do not exacerbate over a maximum 10 years of follow-up. AECOPD frequency in a single year predicts long-term AECOPD rate. Increasing frequency and severity of AECOPDs is associated with risk of death and highlights the importance of preventing AECOPDs.

Entities:  

Keywords:  case–control studies; cohort studies; epidemiology

Mesh:

Year:  2018        PMID: 29474094      PMCID: PMC6118021          DOI: 10.1164/rccm.201710-2029OC

Source DB:  PubMed          Journal:  Am J Respir Crit Care Med        ISSN: 1073-449X            Impact factor:   21.405


  15 in total

1.  Temporal clustering of exacerbations in chronic obstructive pulmonary disease.

Authors:  John R Hurst; Gavin C Donaldson; Jennifer K Quint; James J P Goldring; Ramin Baghai-Ravary; Jadwiga A Wedzicha
Journal:  Am J Respir Crit Care Med       Date:  2008-12-12       Impact factor: 21.405

2.  What does the odds ratio estimate in a case-control study?

Authors:  N Pearce
Journal:  Int J Epidemiol       Date:  1993-12       Impact factor: 7.196

3.  Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease.

Authors:  Bartolome R Celli; Nicholas Locantore; Julie Yates; Ruth Tal-Singer; Bruce E Miller; Per Bakke; Peter Calverley; Harvey Coxson; Courtney Crim; Lisa D Edwards; David A Lomas; Annelyse Duvoix; William MacNee; Stephen Rennard; Edwin Silverman; Jørgen Vestbo; Emiel Wouters; Alvar Agustí
Journal:  Am J Respir Crit Care Med       Date:  2012-03-15       Impact factor: 21.405

4.  Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort.

Authors:  Hana Müllerova; Diego J Maselli; Nicholas Locantore; Jørgen Vestbo; John R Hurst; Jadwiga A Wedzicha; Per Bakke; Alvar Agusti; Antonio Anzueto
Journal:  Chest       Date:  2015-04       Impact factor: 9.410

5.  Exacerbation frequency and course of COPD.

Authors:  David M G Halpin; Marc Decramer; Bartolome Celli; Steven Kesten; Dacheng Liu; Donald P Tashkin
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-09-21

6.  Long-term natural history of chronic obstructive pulmonary disease: severe exacerbations and mortality.

Authors:  Samy Suissa; Sophie Dell'Aniello; Pierre Ernst
Journal:  Thorax       Date:  2012-06-08       Impact factor: 9.139

7.  Risk factors for acute exacerbations of COPD in a primary care population: a retrospective observational cohort study.

Authors:  Hana Müllerová; Amit Shukla; Adam Hawkins; Jennifer Quint
Journal:  BMJ Open       Date:  2014-12-18       Impact factor: 2.692

8.  The impact of exacerbation frequency on mortality following acute exacerbations of COPD: a registry-based cohort study.

Authors:  Sigrun Alba Johannesdottir Schmidt; Martin Berg Johansen; Morten Olsen; Xiao Xu; Joseph M Parker; Nestor A Molfino; Timothy L Lash; Henrik Toft Sørensen; Christian Fynbo Christiansen
Journal:  BMJ Open       Date:  2014-12-19       Impact factor: 2.692

9.  Validity and interpretation of spirometric recordings to diagnose COPD in UK primary care.

Authors:  Kieran J Rothnie; Joht S Chandan; Harry G Goss; Hana Müllerová; Jennifer K Quint
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2017-06-07

Review 10.  Mechanisms and impact of the frequent exacerbator phenotype in chronic obstructive pulmonary disease.

Authors:  Jadwiga A Wedzicha; Simon E Brill; James P Allinson; Gavin C Donaldson
Journal:  BMC Med       Date:  2013-08-14       Impact factor: 8.775

View more
  45 in total

1.  Update in Chronic Obstructive Pulmonary Disease 2018.

Authors:  Wassim W Labaki; Lucas M Kimmig; Gökhan M Mutlu; MeiLan K Han; Surya P Bhatt
Journal:  Am J Respir Crit Care Med       Date:  2019-06-15       Impact factor: 21.405

2.  Relationship between risk, cumulative burden of exacerbations and mortality in patients with COPD: modelling analysis using data from the ETHOS study.

Authors:  Kirsty Rhodes; Martin Jenkins; Enrico de Nigris; Magnus Aurivillius; Mario Ouwens
Journal:  BMC Med Res Methodol       Date:  2022-05-25       Impact factor: 4.612

3.  Short-Term Impact of the Frequency of COPD Exacerbations on Quality of Life.

Authors:  Erin R Camac; Natalie A Stumpf; Helen K Voelker; Gerard J Criner
Journal:  Chronic Obstr Pulm Dis       Date:  2022-07-29

4.  Low serum free light chain is associated with risk of COPD exacerbation.

Authors:  Kazuya Tanimura; Susumu Sato; Atsuyasu Sato; Naoya Tanabe; Koichi Hasegawa; Kiyoshi Uemasu; Yoko Hamakawa; Toyohiro Hirai; Shigeo Muro
Journal:  ERJ Open Res       Date:  2020-07-06

5.  Validation of COPDPredict™: Unique Combination of Remote Monitoring and Exacerbation Prediction to Support Preventative Management of COPD Exacerbations.

Authors:  Neil Patel; Kathryn Kinmond; Pauline Jones; Pamela Birks; Monica A Spiteri
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2021-06-21

6.  Identifying clinically important COPD sub-types using data-driven approaches in primary care population based electronic health records.

Authors:  Maria Pikoula; Jennifer Kathleen Quint; Francis Nissen; Harry Hemingway; Liam Smeeth; Spiros Denaxas
Journal:  BMC Med Inform Decis Mak       Date:  2019-04-18       Impact factor: 2.796

7.  Evaluation of exacerbations and blood eosinophils in UK and US COPD populations.

Authors:  Claus F Vogelmeier; Konstantinos Kostikas; Juanzhi Fang; Hengfeng Tian; Bethan Jones; Christopher Ll Morgan; Robert Fogel; Florian S Gutzwiller; Hui Cao
Journal:  Respir Res       Date:  2019-08-07

8.  Design for a multicenter, randomized, sham-controlled study to evaluate safety and efficacy after treatment with the Nuvaira® lung denervation system in subjects with chronic obstructive pulmonary disease (AIRFLOW-3).

Authors:  Dirk-Jan Slebos; Bruno Degano; Arschang Valipour; Pallav L Shah; Gaetan Deslée; Frank C Sciurba
Journal:  BMC Pulm Med       Date:  2020-02-13       Impact factor: 3.317

Review 9.  Definition, Causes, Pathogenesis, and Consequences of Chronic Obstructive Pulmonary Disease Exacerbations.

Authors:  Andrew I Ritchie; Jadwiga A Wedzicha
Journal:  Clin Chest Med       Date:  2020-09       Impact factor: 2.878

10.  Inhaled corticosteroids in COPD and onset of type 2 diabetes and osteoporosis: matched cohort study.

Authors:  David B Price; Jaco Voorham; Guy Brusselle; Andreas Clemens; Konstantinos Kostikas; Jeffrey W Stephens; Hye Yun Park; Nicolas Roche; Robert Fogel
Journal:  NPJ Prim Care Respir Med       Date:  2019-10-28       Impact factor: 2.871

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.